
CLAIMS

1. Use of a thienopyridone derivative compound of Formula (I):



(I)

wherein:

R1 represents a hydrogen atom or a halogen atom,

R2 represents an indanyl or tetralinyl group, substituted or not by one or more groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

R3 represents an aryl group, substituted or not by one or more atoms or groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, aralkyloxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

or its pharmaceutically acceptable salts and/or solvates,

in the preparation of a medicament in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

2. The use according to claim 1, wherein the thienopyridone derivative compound is to be administered once or twice a day at a daily dose of 0.5mg to 3000 mg for a human patient.

3. The use according to claim 2, wherein the thienopyridone derivative compound is to be administered once or twice a day at a daily dose of 20 mg to 1000 mg.

4. The use according to claim 2, wherein the thienopyridone derivative compound is to be administered once or twice a day at a daily dose of 60 mg to 500 mg.

5. The use according to any one of claims 1 to 4, wherein said thienopyridone derivative compound is effective for preventing or limiting cyst growth or reducing cyst volume.

6. The use according to any one of claims 1 to 5, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom,
- R2 is unsubstituted or substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents,
- the compound of formula (I) is in the form of a salt,
- the compound of formula (I) is in the form of a solvate.

7. The use according to any one of claims 1 to 5, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom,
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted,
- the compound of formula (I) is in the form of a salt,
- the compound of formula (I) is in the form of a solvate.

8. The use according to claims 1 to 7, wherein R1 represents a chlorine atom.


9. The use according to any one of claims 1 to 8, wherein the compound of formula (I) is in the form of a sodium or potassium salt.

10. The use according to any one of claims 1 to 9, wherein the compound of formula (I) is in the form of a solvate and it is a hydrate.

11. The use according to claim 10, wherein the compound of formula (I) is a monohydrate.

12. The use according to any one of claims 1 to 11, wherein the thienopyridone derivative compound is 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-oner, or a pharmaceutically acceptable salt or solvate thereof.

13. The use according to any one of claims 1 to 12 wherein the thienopyridone derivative compound is the monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ia):




(Ia)

14. The use according to any one of claims 1 to 5, wherein at least one of, or all of, the following conditions is met:


- R1 represents a halogen atom,
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is an indanyl group,
- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents.

15. The use according to any one of claims 1 to 5 and 14, wherein the thienopyridone derivative is the 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ib):



(Ib)

16. The use according to any one of claims 1 to 5 and 14, wherein the thienopyridone derivative is the 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ic):



(Ic)

17. The use according to any one of claims 1 to 5, wherein thienopyridone derivative compound of formula (I) is such that:

R1 is Cl,

R2 is an indanyl or tetralinyl group optionally substituted by a hydroxy group, and

R3 is a phenyl group optionally substituted with a halogen,

or a pharmaceutically acceptable salt or solvate thereof.